Nontoxigenic *Corynebacterium diphtheriae* strains were recovered from approximately 1 per 1,000 throat swabs from immunized British military personnel in Germany from 1993 to 1995 [@R1]. Such nontoxigenic *C. diphtheriae* biotype *mitis* isolates had been described in skin, throat, and blood cultures of Swiss injecting drug users; 32 of the isolates belonged to the same clone ([@R2],[@R3]). Our study demonstrates that this clone and closely related clones occurred between 1990 and 1997 in two other European countries, and only sometimes in persons with poor hygiene.

Five *C. diphtheriae* isolates came from two laboratories in Zurich and Bern, Switzerland; 11 from four laboratories in Hamburg, Germany; and 1 from Paris, France (Table). They were identified in Zurich as *C. diphtheriae* biotype *mitis* [@R4]; that is, they were nonlipophilic, were nitrate reductase-positive, and did not ferment glycogen. By polymerase chain reaction techniques [@R5], the diphtheria toxin gene was not detected in any isolate. For some isolates, the Elek test was also performed; it was consistently negative. For ribotyping, DNA was isolated, digested with either *Eco*RI or *Pvu*II, electrophoresed, blotted, and probed for rDNA as described elsewhere ([@R2],[@R3]). Disk susceptibility testing to tetracycline and MIC determinations were done according to National Committee for Clinical Laboratory Standards methods [@R6]. All other bacteria isolated were also identified and serotyped in Zurich.

###### Nontoxigenic Corynebacterium diphtheriae isolates

  Isolate no.   Date isolateda   Place of isolationb   Ribotyping pattern^c^   Patients sex, age (yr)   Clinical diagnosis/source   Other bacteria isolated           Underlying conditions                                       
  ------------- ---------------- --------------------- ----------------------- ------------------------ --------------------------- --------------------------------- ----------------------------------------------------------- -----------------------------------------------------
  2012          1990             Paris                 A                       C                        m, 6                        Endocarditis/blood culture        ---                                                         Skin lesions,scabies
  2410          2/1995           Hamburg               A                       B                        m, 30                       Ulcus/lower leg                   Staphylococcus aureus, Streptococcus pyogenes               Prisoner
  2689          3/1995           Hamburg               A                       A                        f, 82                       Puncture/hip joint                S. epidermidis, Corynebacterium pseudodiphtherit- icum      Total hip jointendoprosthesis
  1682          9/1995           Hamburg               A                       B                        m, 45                       Wound swab                        S. aureus, S. pyogenes                                      Homelessness
  1935          3/1996           Hamburg               A                       B                        m, 58                       Wound swab                        S. aureus, S. pyogenes                                      Alcoholism, homelessness
  1836          3/1996           Hamburg               A                       B                        m, 45                       Abscess/lower leg                 S. aureus, S. pyogenes                                      Injecting drug use
  2661          3/1996           Hamburg               A                       A                        m, 35                       Arthroscopy aspirate/knee joint   Peptostreptococcus prevotii,P. magnus                       Osteosynthesis, arthrotomy, knee joint after trauma
  2658          4/1996           Hamburg               A                       A                        f, 76                       Fistula/hip joint                 S. aureus                                                   Total hip joint endoprosthesis
  2674          5/1996           Hamburg               A                       A                        f, 62                       Aspirate/hip joint                Streptococcus group C                                       Total hip joint endoprosthesis
  2670          7/1996           Hamburg               A                       A                        f, 81                       Aspirate/knee joint               ---                                                         Total knee joint endoprosthesis
  2667          7/1996           Hamburg               A                       A                        m, 23                       Swab/hip joint                    Coagulase-negative staphylococci                            Total hip joint endoprosthesis
  2413          11/1996          Hamburg               A                       B                        m, 36                       Ulcus/lower leg                   S. aureus, Streptococcus group C/G                          Prisoner
  2446          12/1996          Zurich                A                       A                        f, 38                       Wound/upper leg                   S. aureus, S. pyogenes                                      Injecting drug use
  2464          1/1997           Zurich                A                       A                        m, 39                       Ulcera/lower arm                  Escherichia coli, S. aureus, S. pyogenes                    Injecting drug use
  2473          1/1997           Zurich                A                       A                        m, 38                       Ulcera/leg                        E. coli, Streptococcus group C, G                           Injecting drug use
  2475          1/1997           Zurich                A                       A                        m, 31                       Ulcus/pretibial                   Pseudomonas aeruginosa, E. coli, Streptococcus group C, G   Injecting drug use
  480           5/1997           Bern                  A                       A                        m, 39                       Ulcus/upper leg                   S. aureus, Clostridium perfringens, mixed anaerobic flora   Injecting drug use

^a^Month/Year ~b~Paris, France; Hamburg, Germany; Zurich, Switzerland; Bern, Switzerland. ^c^DNA was isolated, digested with either EcoRI or PvuII, electrophoresed, blotted, and probed for DNA. Three distinct ribopatterns emerged, each with eight bands: patterns A, B, and C.

Many (10 \[59%\] of 17) *C. diphtheriae* isolates were from skin or subcutaneous infections (wounds, ulcers) in Swiss patients and were found with *Staphylococcus aureus, Streptococcus pyogenes,* group C/G streptococci, or (sometimes) with gram-negative rods. Most patients in this subgroup were injecting drug users, homeless persons, prisoners, and (with one exception) men with a mean age of 40 (30 to 58) years. Another subgroup (from Germany) consisted of six patients with joint or bone infections (mentioned briefly in an earlier publication on coryneform bacteria from such infections; a seventh patient had *C. diphtheriae* biotype *gravis* \[[@R7]\]). The six had been hospitalized at the Endo Clinic in Hamburg, which specializes in orthopedic surgery. Four had had implantations of hip endoprostheses and had been admitted for prosthetic infections (with coagulase-negative staphylococci or *S. aureus)*; one pure culture of *C. diphtheriae* biotype *mitis* was obtained from a patient with a knee prosthesis, and one mixed culture with *Peptostreptococcus magnus* and *Peptostreptococcus prevotii* was obtained from a patient who had a purulent knee infection after a fracture. Their average age was 60 (23 to 82) years and, to our knowledge, none was a drug user. While the Hamburg isolates were recovered only once from every patient, their isolation dates stretched from March 1, 1995, until July 26, 1996. Three were isolated on the day of admission, and all of them were isolated by different technologists. Finally, one child (from France) had endocarditis with *C. diphtheriae* biotype *mitis.*

All isolates had identical antimicrobial susceptibility patterns. They were susceptible to amoxicillin (MIC, 0.25 µg/ml), amoxicillin-clavulanic acid (0.06 µg/ml), chloramphenicol (2 µg/ml), ciprofloxacin (0.25 µg/ml), clarithromycin (0.03 µg/ml), clindamycin (0.25 µg/ml), imipenem (0.03 µg/ml), penicillin (0.25 µg/ml), and vancomycin (1 µg/ml). In contrast, all strains were resistant to tetracycline in the disk diffusion test (inhibition zone diameter 10 mm to 11 mm); their MICs for tetracycline, doxycycline, and minocycline were 64 µg/ml, 16 µg/ml, and 16 µg/ml, respectively. While this type of isolated tetracycline resistance was typical for the isolates from Swiss injecting drug users [@R3], tetracycline resistance in nontoxigenic *C. diphtheriae* has otherwise very rarely been observed in Europe [@R8]. It has, however, been reported in toxigenic *C. diphtheriae* isolates from Indonesia and, rarely, from Canada [@R9]. The mechanism conferring this resistance in our strains has not been investigated.

On analysis with restriction enzyme *Pvu* II, three different ribopatterns with eight bands each were found among the strains ([Figure](#F1){ref-type="fig"}). These patterns, though distinct, shared five (A vs. C, B vs. C) and six (B vs. A) bands, respectively, and, therefore, may be considered related, as they would be if criteria for pulsed-field gel electrophoresis were applied [@R10]. This view is supported by the fact that all strains had identical *Eco*RI patterns (not shown). All Swiss isolates were identical with the use of both enzymes, whereas both the Swiss pattern and a second pattern were found among the Hamburg isolates. The third pattern was found exclusively in the single French strain. The staphylococcal and streptococcal strains were not typed; they are no longer available to us.

![Ribosomal RNA gene restriction patterns obtained by using restriction enzyme Pvu II of *Corynebacterium diphtheriae* isolates belonging to ribotypes B (lanes 1 to 3), A (lanes 4 to 6 and 8), and C (lane 7).](99-0326-F){#F1}

Our isolates thus resemble those reported from Switzerland between 1990 and early 1996 ([@R2],[@R3]), which were also often accompanied by *S. aureus* or beta-hemolytic streptococci. Such nontoxigenic *C. diphtheriae mitis* may cause endocarditis, arthritis, and osteomyelitis ([@R11],[@R12]). Most of the 52 isolates from France [@R11], examined with restriction enzymes different from ours and not available to us, also belonged to one ribotype. Their relatedness to our strains is unknown; however, they were largely tetracycline-susceptible. The two throat isolates from St. Petersburg, Russia, associated with a fatal diphtherialike disease [@R12] were not typed or tested for antibiotic susceptibility.

The origin of the isolates we describe is unknown. They may have been present (but unrecognized) in the population for a long time. The mode of transmission is most likely common use of drug paraphernalia in the injecting drug use cases and in the endocarditis case; transmission is very difficult to explain in the orthopedic infection subgroup. Although the Swiss and the Danish borders are not close, migration and contacts are not uncommon among injecting drug users. The isolates may also have been distributed through the drugs themselves, as recently reported for *S. pyogenes* in Switzerland [@R13].

Our study may be representative for Switzerland and Germany, but since submitting *C. diphtheriae* strains to a central reference laboratory in these countries is not mandatory, we cannot estimate the frequency of these strains. These strains may also have spread to other European countries; this hypothesis can only be tested in a large multicenter study of European diphtheria reference laboratories.
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